HEALTH CARE:
PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Arca Biopharma discovers, develops and commercializes novel products for acute cardiovascular indications and cancer. As of March 2005, the company had three drug candidates in clinical trials, including its lead candidate, alfimeprase, a thrombolytic agent.
Market Cap | 43.438 Million | Shares Outstanding | 9.321 Million | Avg 30-day Volume | 606.903 Thousand |
P/E Ratio | -1.8 | Dividend Yield | EPS | -2.58 | |
Price/Sales | Price cash flow ratio | Price free cash flow ratio | -9.2 | ||
Book Value | 5.41 | Price to Tangible Book | 0.86 | Alpha | -0.04 |
Short Interest Ratio | % Short Interest to Float | R-squared | 0.106909 | ||
BETA | 2.8033 | 52-week High/Low | 22.0 / 2.21 | Stddev | 0.377264 |
Q3 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 0 | 0 | 0 (0.0%) | 0 (0.0%) | ||
Funds Holding: | 16 | 9 | 77.78% | 4 (0.26%) | 2 (0.13%) | 100.0% |
13F shares: | 412.187 Thousand | 135.831 Thousand | 203.46% | 66.722 Thousand | 103.191 Thousand | -35.34% |
% Ownership | 6.98 | 2.3002 | 203.45% | 1.1299 | 1.7474 | -35.34% |
New Positions: | 8 | 3 | ||||
Increased Positions | 3 | 1 | 200.0% | |||
Closed Positions | 1 | 4 | -75.0% | 1 | ||
Reduced Positions | 2 | 3 | -33.33% | 1 | 2 | -50.0% |
Total Calls | 0 | |||||
Total Puts | 0 | |||||
PUT/CALL Ratio | ||||||
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
10 Thousand total shares from 1 transactions
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2021-01-12 | 1 | |
|
0 | 2021-01-12 | 1 | |
|
30,000 | 2021-01-12 | 5 | |
|
611 | 2021-01-12 | 1 | |
|
0 | 2021-01-12 | 1 | |
OZEROFF CHRISTOPHER DAVID S.V.P., GENERAL COUNSEL |
|
970 | 2020-12-21 | 1 |
BRISTOW MICHAEL R PRES. & CHIEF EXECUTIVE OFFIC |
|
4,808 | 2020-12-21 | 1 |
SELBY BRIAN L. VP, FINANCE |
|
0 | 2020-12-21 | 1 |
KEUER THOMAS A CHIEF OPERATING OFFICER |
|
730 | 2020-12-21 | 1 |
|
No longer subject to file | 2018-02-26 | 0 | |
|
No longer subject to file | 2018-02-26 | 0 | |
GROWTH EQUITY OPPORTUNITIES IV, LLC |
|
No longer subject to file | 2018-02-26 | 0 |
|
No longer subject to file | 2018-02-26 | 0 | |
|
No longer subject to file | 2018-02-26 | 0 | |
|
No longer subject to file | 2018-02-26 | 0 | |
|
No longer subject to file | 2018-02-26 | 0 | |
|
No longer subject to file | 2018-02-26 | 0 | |
|
No longer subject to file | 2018-02-26 | 0 | |
|
No longer subject to file | 2018-02-26 | 0 | |
VENROCK HEALTHCARE CAPITAL PARTNERS LP VHCP CO-INVESTMENT HOLDINGS, LLC VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P. |
|
No longer subject to file | 2018-02-26 | 0 |
VENROCK HEALTHCARE CAPITAL PARTNERS LP VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P. VHCP CO-INVESTMENT HOLDINGS, LLC |
|
10,789,324 | 2015-06-16 | 0 |
|
10,221,465 | 2015-06-16 | 0 | |
|
10,221,465 | 2015-06-16 | 0 | |
|
No longer subject to file | 2015-01-14 | 0 | |
WHEELER PATRICK M CHIEF FINANCIAL OFFICER |
|
101,510 | 2014-09-18 | 0 |
|
0 | 2013-09-17 | 0 | |
|
1,579,542 | 2012-10-25 | 0 | |
|
1,579,542 | 2012-10-22 | 0 | |
|
0 | 2012-02-10 | 0 | |
|
0 | 2012-02-10 | 0 | |
|
1,337,612 | 2010-03-29 | 0 | |
|
0 | 2010-02-05 | 0 | |
|
0 | 2010-02-05 | 0 | |
|
0 | 2010-02-05 | 0 | |
|
No longer subject to file | 2009-07-17 | 0 | |
FALBERG KATHRYN E CFO AND COO |
|
0 | 2009-06-25 | 0 |
|
No longer subject to file | 2009-06-11 | 0 | |
JONES ANDREW E |
|
No longer subject to file | 2009-04-06 | 0 |
ST LAURENT RANDALL EVP COMMERCIAL OPERATIONS |
|
0 | 2009-01-27 | 0 |
BENDEKGEY E LEE CFO AND TREASURER |
|
1,502 | 2008-12-31 | 0 |
|
0 | 2008-06-04 | 0 | |
|
0 | 2008-06-04 | 0 | |
|
0 | 2008-06-04 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-01-13 19:06:01 -0500 | 2021-01-12 | A | 12,000 | a | 12,000 | direct | ||||||||||
2021-01-13 19:05:18 -0500 | 2021-01-12 | A | 12,000 | a | 12,000 | direct | ||||||||||
2021-01-13 19:06:34 -0500 | 2021-01-12 | A | 12,000 | a | 12,000 | direct | ||||||||||
2021-01-13 19:07:09 -0500 | 2021-01-12 | A | 12,000 | a | 12,000 | direct | ||||||||||
2021-01-13 19:04:38 -0500 | 2021-01-12 | A | 12,000 | a | 12,000 | direct | ||||||||||
BRISTOW MICHAEL R - Director - Officer PRES. & CHIEF EXECUTIVE OFFIC |
2020-12-23 16:15:08 -0500 | 2020-12-21 | A | 190,000 | a | 190,000 | direct | |||||||||
2020-12-23 16:47:42 -0500 | 2020-12-21 | A | 70,000 | a | 70,000 | direct | ||||||||||
2020-12-23 16:15:11 -0500 | 2020-12-21 | A | 55,000 | a | 55,000 | direct | ||||||||||
2020-12-23 16:15:08 -0500 | 2020-12-21 | A | 55,000 | a | 55,000 | direct | ||||||||||
2020-12-21 16:15:11 -0500 | 2020-12-18 | P | 10,000 | $4.16 | a | 30,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |